Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01933282
Other study ID # MESA-NKT2013
Secondary ID
Status Recruiting
Phase Phase 2
First received August 16, 2013
Last updated December 21, 2013
Start date January 2013
Est. completion date January 2015

Study information

Verified date December 2013
Source Fourth Military Medical University
Contact RONG LIANG, professor
Phone 86 13384933870
Email rongliang1017@gmail.com
Is FDA regulated No
Health authority China: Ministry of HealthChina: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma


Description:

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%. The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western countries. Despite radiotherapy and chemotherapy, the prognosis for ENKTL patients is poor, with 5-year median survival time for primary nasal site was 5 years, for non-nasal extranodal sites 6 months. ENKTL is so aggressive and has high mortality rate and till now there is no standard therapy. In recent years SMILE chemotherapy has clinical efficacy and is one of first line therapy for ENKTL. However it is apparent that this regimen is extremely toxic with grade 4 neutropenia especially for Asian patients. On these grounds, new therapy MESA is used for Asian patients with ENKTL in order to achieve good efficacy and safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group 15 Years to 60 Years
Eligibility Inclusion Criteria:

- Pathological diagnosis is NK/T cell lymphoma;

- At least one objective evaluation ( measurable ) lesions

- Age 15 ~ 60 years old, men and women are not limited

- ECOG(Eastern Cooperative Oncology Group)performance status 0~3,Expected to survive more than 3 months;

- Heart, kidney function in the normal range

- Liver function: transminase< 2 times the normal value

- pregnancy tests of women childbearing age must be negative; Men and women agree to use effective contraception during the treatment and the following year

- Before the test sign the written informed consent

Exclusion Criteria:

- The early use of methotrexate or/and L-asparaginase;

- Pregnant or nursing, psychiatric patients complicated with malignant tumor

- At the same time the application of other trial drug, drug contraindications exist in research;

- Serious infection or metabolic diseases

- Liver dysfunction, serum direct bilirubin, indirect bilirubin, transaminase 2 times higher than normal; serum total protein or albumin below normal;

- Renal insufficiency, creatinine clearance rate was 2 times higher than normal, especially the creatinine clearance rate is less than 30ml/min;

- Before entering the group, blood: White blood cell< 3×10E9/L; absolute neutrophil count<1.5×10E9/L; platelet<100×10E9/L ( bone marrow is not violated ); platelet count <75×10E9/L ( bone marrow invasion ); hemoglobin<100g/L.

- In the 6 months before entering the group, patients with uncontrolled or serious cardiovascular diseases, including myocardial infarction, III-IV class heart failure, uncontrolled angina or clinically significant pericardial disease, and diabetes and phlebitis;

- HIV antibody positive, HBsAg positive after antiviral HBV(hepatitis B virus) DNA titer in 104copies/ml the following groups. HIV antibody positive, HBsAg+ and DNA titer in 104copies/ml after antiviral HBV therapy

- Coagulation abnormalities.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
MESA chemotherapy
Methotrexate 2g/ m2,IV d1 etoposide 100mg/ m2,VD d2,d3,d4, dexamethasone 20mg/ m2,VD d2,d3,d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
MESA
Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase

Locations

Country Name City State
China Department of Hemaology, Xi jing Hospital,The Fourth Military Medical University Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Fourth Military Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary response criteria for CR(complete remission)by physical examination,lymph nodes masses and bone marrow test. After 6 cycle of MESA treatment,response assessments for CR,PR(partial remission) and NR(no remission) should include appropriate imaging studies(CT,MRI and PET-CT) based on the type of study performed at initial workup, endoscopy with visual inspection, repeat biopsies and measurement of EBV DNA 24 week Yes
Secondary rate of survival prognosis assessment by rates of survival including PFS(Progression-Free-Survival) and OS(Overall survival)at 1 year,2 years,3 years after induction therapies and follow up therapies. 1 year, 2 years, 3years Yes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02878278 - Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation Phase 2
Terminated NCT01948180 - Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Phase 2
Completed NCT00069238 - Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Phase 2
Recruiting NCT03646422 - AEDV Registry of Primary Cutaneous Lymphoma
Terminated NCT02359162 - Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage Phase 3
Recruiting NCT02080234 - Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL Phase 2
Completed NCT03049449 - T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Phase 1
Not yet recruiting NCT03051555 - 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma N/A
Not yet recruiting NCT03051542 - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma N/A
Recruiting NCT03154918 - GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma Phase 2
Terminated NCT02533323 - P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens Phase 2
Active, not recruiting NCT03439501 - Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] Phase 2
Recruiting NCT04417166 - Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma Phase 2
Recruiting NCT02859402 - Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas Phase 2